Korean J Intern Med 2016;31(3):525-534.
a p < 0.05 when compared with HCAP.
b p < 0.05 when compared with CAP.
c Chronic lung disease includes chronic obstructive lung disease and structural lung diseases, such as bronchiectasis.
a Hospitalization in an acute care hospital for 2 or more days within 90 days of the infection.
b Infusion therapy, such as intravenous antibiotic therapy, chemotherapy, or wound care, within 30 days of a current infection.
c Residence in a nursing home or long-term care facility.
d Regular attendance at a dialysis clinic, including hemodialysis and peritoneal dialysis.
a Numbers include mixed population of pathogens (4 in CAP, 7 in HCAP, and 9 in HAP).
b ESBL producing Enterobacteriae include Klebsiella pneumoniae, Escherichia coli, Enterobacter spp.
c MDR Pseudomonas spp. means resistant Pseudomonas aeruginosa.
d p < 0.05 when compared with CAP.
b Broad spectrum antibiotic use was defined as the use of any antibiotics including antipseudomonal β-lactamase or vancomycin or carbapenem.
c p < 0.05 when compared with CAP.
d Treatment failure means death during initial treatment or change of empirical antibiotics from the initial agents to others on the 7th day from medical intensive care unit admission.
a A total of 92 patients were successfully weaned from mechanical ventilation in the ICU.
b ICU free days refers to the period from ICU discharge to hospital discharge.
a Compared with healthcare-acquired pneumonia.
b Change of empirical antibiotics from initial agents to others within the 7th day.
3. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.
5. Sopena N, Sabria M, Neunos 2000 Study Group. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest 2005;127:213–219.